FDA Inspection 1252996 — Anna Dryja, MD, MBA
The FDA completed an inspection of Anna Dryja, MD, MBA on October 18, 2024 in Warsaw. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions were found but do not meet the threshold for regulatory action). Product area: Drugs.
Inspection Details
- Classification
- Voluntary Action Indicated (VAI) (VAI)
- End Date
- October 18, 2024
- Fiscal Year
- 2025
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Warsaw (Poland)
Additional Details
Clinical BA/BE